IV ITRACONAZOLE VS AMPHOTERICIN B IN BLASTOMYCOSIS OR HISTOPLASMOSIS

这项研究的主要目的是评估静脉注射伊曲康唑的安全性，并与治疗标准(两性霉素B)进行比较。这项研究还将评估静脉诱导治疗结束(7-14天)以及PO巩固治疗后2、12和24周的临床、微生物学和总体反应。患者将随机接受伊曲康唑静脉注射，每天两次，持续两天(负荷量)，然后每天一次，持续5天，或两性霉素-B静脉注射，持续7天。如果临床情况需要，将允许延长治疗时间。在静脉注射治疗后，伊曲康唑胶囊每天一次，每天两次，持续一年。在诱导治疗期间(7-14天)，静脉滴注伊曲康唑超过一小时。根据治疗的副作用，静脉注射两性霉素-B的时间为1-6小时。在巩固治疗期间，口服伊曲康唑每天一次或一天两次，疗程长达一年。

The primary purpose of this study is to assess the safety of IV itraconazole compared to the standard of care (Amphotericin B). The study will also assess the clinical, microbiological, and overall response to therapy at the end of IV induction therapy (7-14 days) and after PO consolidation therapy at 2, 12, and 24 weeks. Patients will be randomized to either an initial treatment with IV itraconazole twice a day for 2 days (loading dose) and then once a day for 5 additional days or amphotericin-B IV for 7 days. Extended treatment would be allowed if the clinical condition required it. IV treatment will be followed by consolidation therapy with itraconazole capsules once daily for twice a day for up to one year. During induction therapy (7-14 days) IV itraconazole is infused over a one-hour period of time. IV Amphotericin-B is infused over a 1-6 hour period of time depending on the side effects to therapy. During consolidation therapy oral itraconazole is given either once a day or twice a day for up to 1 year.